JMP reiterates Genomic Health at market outperform

Genomic Health, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating at a $16 price target after the company presented compelling data on Oncotype DX at a medical conference. These presentations confirm and extend previous data on the reliability, specificity and sensitivity of using the company's quantitative, gene-based prognostic assay to determine probability of tumor recurrence. Shares of the Redwood City, Calif., oncology-based biotechnology company were up 63 cents, or 6.27%, at $10.68 on volume of 53,150 shares versus the three-month running average of 86,456.2 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.